HUP9900592A3 - Process for testing the purity of pharmaceutical composition containing lamotrigine - Google Patents
Process for testing the purity of pharmaceutical composition containing lamotrigineInfo
- Publication number
- HUP9900592A3 HUP9900592A3 HU9900592A HUP9900592A HUP9900592A3 HU P9900592 A3 HUP9900592 A3 HU P9900592A3 HU 9900592 A HU9900592 A HU 9900592A HU P9900592 A HUP9900592 A HU P9900592A HU P9900592 A3 HUP9900592 A3 HU P9900592A3
- Authority
- HU
- Hungary
- Prior art keywords
- purity
- testing
- pharmaceutical composition
- composition containing
- containing lamotrigine
- Prior art date
Links
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 title 1
- 229960001848 lamotrigine Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9812413.4A GB9812413D0 (en) | 1998-06-10 | 1998-06-10 | Compound and its use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU9900592D0 HU9900592D0 (en) | 1999-04-28 |
| HUP9900592A2 HUP9900592A2 (hu) | 2000-04-28 |
| HUP9900592A3 true HUP9900592A3 (en) | 2002-04-29 |
Family
ID=10833464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9900592A HUP9900592A3 (en) | 1998-06-10 | 1999-03-10 | Process for testing the purity of pharmaceutical composition containing lamotrigine |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6333198B1 (hu) |
| EP (2) | EP0963980B1 (hu) |
| JP (1) | JP2989189B1 (hu) |
| KR (1) | KR100322354B1 (hu) |
| CN (2) | CN1238454A (hu) |
| AP (3) | AP9901481A0 (hu) |
| AR (1) | AR014074A1 (hu) |
| AT (1) | ATE218552T1 (hu) |
| AU (1) | AU2031999A (hu) |
| BR (1) | BR9900984A (hu) |
| CA (1) | CA2265194C (hu) |
| DE (1) | DE69901656T2 (hu) |
| DK (1) | DK0963980T3 (hu) |
| EA (1) | EA000666B1 (hu) |
| ES (1) | ES2178342T3 (hu) |
| GB (1) | GB9812413D0 (hu) |
| HR (1) | HRP990074A2 (hu) |
| HU (1) | HUP9900592A3 (hu) |
| ID (1) | ID22957A (hu) |
| MA (1) | MA24777A1 (hu) |
| NO (2) | NO991151L (hu) |
| NZ (1) | NZ334590A (hu) |
| PE (1) | PE20000332A1 (hu) |
| PL (1) | PL331870A1 (hu) |
| PT (1) | PT963980E (hu) |
| SG (1) | SG85628A1 (hu) |
| SI (1) | SI0963980T1 (hu) |
| TR (1) | TR199900520A2 (hu) |
| UY (1) | UY25946A1 (hu) |
| YU (1) | YU12399A (hu) |
| ZA (1) | ZA991951B (hu) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020055177A1 (en) * | 1999-03-10 | 2002-05-09 | Glaxo Wellcome Inc. | Compound and its use |
| AU763244B2 (en) * | 2000-01-03 | 2003-07-17 | Rpg Life Sciences Limited | A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine |
| US7335380B2 (en) | 2000-12-29 | 2008-02-26 | Synthon Ip Inc. | Amlodipine free base |
| MXPA03005884A (es) | 2000-12-29 | 2005-04-08 | Pfizer Ltd | Hemimaleato de amlodipina. |
| SI1309555T1 (sl) | 2000-12-29 | 2005-12-31 | Pfizer Ltd | Postopek izdelave amlodipin-maleata |
| AT5874U1 (de) | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| MXPA03005886A (es) | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado de aspartato de amlodipina como antagonista del canal de calcio. |
| MXPA03005882A (es) | 2000-12-29 | 2005-04-19 | Pfizer Ltd | Derivado amida de amlodipina. |
| WO2002054062A2 (en) * | 2000-12-29 | 2002-07-11 | Pfizer Limited | Reference standards and processes for determining the purity or stability of amlodipine maleate |
| CA2433181C (en) | 2000-12-29 | 2005-11-22 | Pfizer Limited | Amlodipine hemifumarate |
| US6653481B2 (en) | 2000-12-29 | 2003-11-25 | Synthon Bv | Process for making amlodipine |
| BR0116554A (pt) | 2000-12-29 | 2004-02-03 | Pfizer Ltd | Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão |
| DE10134980C2 (de) | 2001-07-17 | 2003-05-28 | Helm Ag | Verfahren zur Herstellung von Lamotrigin |
| CA2366521C (en) | 2001-12-24 | 2007-03-06 | Brantford Chemicals Inc. | A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines |
| US20030216376A1 (en) * | 2002-03-20 | 2003-11-20 | Revital Lifshitz-Liron | Crystalline forms of quetiapine hemifumarate |
| HU225667B1 (en) * | 2002-09-20 | 2007-05-29 | Richter Gedeon Nyrt | Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine |
| ES2209639B1 (es) | 2002-10-31 | 2005-08-01 | Vita Cientifica, S.L. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio. |
| GB2395483A (en) * | 2003-07-03 | 2004-05-26 | Jubilant Organosys Ltd | Crystalline lamotrigine and its monohydrate |
| EP1562912A2 (en) | 2003-08-28 | 2005-08-17 | Teva Pharmaceutical Industries Limited | Process for preparation of rosuvastatin calcium |
| CA2546701C (en) * | 2003-11-24 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| KR100887264B1 (ko) | 2003-12-02 | 2009-03-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로수바스타틴의 특성화를 위한 기준 표준물 |
| US7851624B2 (en) * | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
| EP1708708A1 (en) * | 2004-01-30 | 2006-10-11 | Teva Pharmaceutical Industries Ltd. | Montelukast free acid polymorphs |
| CA2554789A1 (en) * | 2004-01-30 | 2005-08-18 | Teva Pharmaceutical Industries, Ltd. | Montelukast sodium polymorphs |
| MD2823G2 (ro) * | 2004-02-12 | 2006-05-31 | Институт Химии Академии Наук Молдовы | Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat |
| JP2007532686A (ja) * | 2004-04-21 | 2007-11-15 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカストナトリウムを調製する方法 |
| JP2007532585A (ja) | 2004-04-26 | 2007-11-15 | テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ | ミコフェノール酸及びそのエステル誘導体の調製方法 |
| EP1740563A2 (en) * | 2004-04-27 | 2007-01-10 | Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság | Mycophenolate mofetil impurity |
| US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
| ATE407111T1 (de) * | 2004-06-28 | 2008-09-15 | Teva Pharm Fine Chemicals Srl | Isolierte atomoxetinverunreinigung, verfahren zur herstellung von atomoxetinverunreinigungen und deren verwendung als referenzstandards |
| US7179916B2 (en) * | 2004-07-13 | 2007-02-20 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin |
| WO2006012379A2 (en) * | 2004-07-20 | 2006-02-02 | Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg | Processes for preparation of crystalline mycophenolate sodium |
| WO2006020348A2 (en) * | 2004-07-22 | 2006-02-23 | Teva Pharmaceutical Fine Chemicals S.R.L. | Polymorphs of atomoxetine hydrochloride |
| CA2578750A1 (en) * | 2004-09-04 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard |
| US20060081361A1 (en) * | 2004-09-13 | 2006-04-20 | Gabbey Lawrence W | Oil cooler with integral filter |
| ES2263407T1 (es) * | 2004-09-28 | 2006-12-16 | Teva Pharmaceutical Industries Ltd | Procedimiento para la preparacion de formas de atorvastatina calcica sustancialmente libres de impurezas. |
| CA2582090A1 (en) * | 2004-10-19 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Purification of tegaserod maleate |
| US7678551B2 (en) * | 2004-10-25 | 2010-03-16 | Seradyn, Inc. | Immunoassays for lamotrigine |
| WO2006071868A2 (en) * | 2004-12-23 | 2006-07-06 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof |
| PT1836157E (pt) * | 2005-01-11 | 2009-11-24 | Teva Pharm Fine Chemicals Srl | Polimorfos de cloridrato de memantina |
| US20070037979A1 (en) * | 2005-02-22 | 2007-02-15 | Valerie Niddam-Hildesheim | Preparation of rosuvastatin |
| ES2389565T3 (es) | 2005-02-22 | 2012-10-29 | Teva Pharmaceutical Industries Ltd. | Rosuvastatina y sales de la misma carentes de alquiléter de rosuvatatina y un procedimiento para la preparación de las mismas |
| US20070167625A1 (en) * | 2005-02-22 | 2007-07-19 | Anna Balanov | Preparation of rosuvastatin |
| CA2602073A1 (en) * | 2005-02-24 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of linezolid intermediate |
| US7534900B2 (en) * | 2005-03-14 | 2009-05-19 | Teva Pharmaceutical Industries Ltd | Process for the purification of duloxetine hydrochloride |
| US7569729B2 (en) * | 2005-04-05 | 2009-08-04 | Teva Pharmaceutical Fine Chemicals S.R.L. | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
| CN101160281A (zh) * | 2005-04-06 | 2008-04-09 | 特瓦制药工业有限公司 | 结晶形态的普瑞巴林 |
| US7488846B2 (en) * | 2005-04-11 | 2009-02-10 | Teva Pharmaceuical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
| US20070066846A1 (en) * | 2005-04-11 | 2007-03-22 | Asher Maymon | Process for making (S)-Pregabalin |
| JP2008502707A (ja) * | 2005-04-14 | 2008-01-31 | テバ ファーマシューティカル インダストリーズ リミティド | クエチアピンフマレートの調製方法 |
| US20080280977A1 (en) * | 2005-04-26 | 2008-11-13 | Sandor Molnar | Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid |
| CA2604600A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Pregabalin free of isobutylglutaric acid and a process for preparation thereof |
| KR100893312B1 (ko) * | 2005-05-10 | 2009-04-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 프레가발린 및 이의 염의 제조 방법 |
| CA2604624A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid |
| WO2006121557A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
| EP1975150A1 (en) | 2005-05-23 | 2008-10-01 | Teva Pharmaceutical Industries Ltd. | Cinacalcet salts |
| WO2007002720A2 (en) * | 2005-06-27 | 2007-01-04 | Sicor, Inc. | An impurity of anastrozole intermediate, and uses thereof |
| KR20080015438A (ko) * | 2005-06-27 | 2008-02-19 | 시코르, 인크. | 아나스트로졸 중간체의 불순물, 및 이의 용도 |
| JP2008510840A (ja) * | 2005-07-05 | 2008-04-10 | テバ ファーマシューティカル インダストリーズ リミティド | モンテルカストの精製 |
| WO2007022488A2 (en) * | 2005-08-16 | 2007-02-22 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
| KR20070087596A (ko) * | 2005-09-19 | 2007-08-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | (ｓ)-(+)-3-(아미노메틸)-5-메틸헥산산의 비대칭 합성 |
| US20070197529A1 (en) * | 2005-12-01 | 2007-08-23 | Viviana Braude | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard |
| US7759500B2 (en) * | 2005-12-05 | 2010-07-20 | Teva Pharmaceutical Industries Ltd. | 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride |
| WO2007069264A2 (en) * | 2005-12-15 | 2007-06-21 | Alembic Limited | Reference standards for determining the purity of telithromycin and processes therefor |
| US20070203221A1 (en) * | 2005-12-27 | 2007-08-30 | Valeriano Merli | Processes for preparing darifenacin hydrobromide |
| CA2644819A1 (en) * | 2006-03-27 | 2007-11-08 | Teva Pharmaceutical Fine Chemicals S.R.L. | Process for preparing memantine hydrochloride substantially free of impurities |
| US20080146675A1 (en) * | 2006-04-05 | 2008-06-19 | Eugenio Castelli | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
| GB0609835D0 (en) * | 2006-05-18 | 2006-06-28 | Pliva Istrazivanje I Razvoj D | Impurities of a pharmaceutical product |
| KR20080027880A (ko) * | 2006-05-24 | 2008-03-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | Ｒ-(+)-3-(카바모일메틸)-5-메틸헥산산 및 이의 염의 제조방법 |
| EP1912931A2 (en) * | 2006-05-31 | 2008-04-23 | Teva Pharmaceutical Industries Ltd. | Preparation of (s)-pregabalin-nitrile |
| KR20080036060A (ko) * | 2006-05-31 | 2008-04-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 프레가발린의 중간체의 제조에 효소 분할을 이용하는 방법 |
| ES2339297T3 (es) * | 2006-06-29 | 2010-05-18 | Ivax Pharmaceuticals S.R.O. | Regulacion de la produccion de metabolitos acidos. |
| US20120142919A1 (en) * | 2006-08-02 | 2012-06-07 | Medichem, S.A. | Method for synthesizing lamotrigine |
| CN101506178A (zh) * | 2006-08-14 | 2009-08-12 | 隆沙有限公司 | 制备拉莫三嗪的方法 |
| EP2139845A1 (en) * | 2007-02-26 | 2010-01-06 | Teva Pharmaceutical Industries Ltd. | Intermediates and processes for the synthesis of ramelteon |
| BRPI0803092A2 (pt) * | 2007-03-22 | 2011-08-30 | Teva Pharma | sìntese de (s)-(+)-3-(aminometil)-5-metil ácido hexanóico, (s)-pregabalina |
| BRPI0803097A2 (pt) * | 2007-04-11 | 2011-11-08 | Teva Gyogyszergyar ... | método para redução do nìvel de impurezas na fermentação do ácido micofenólico |
| WO2008151170A2 (en) * | 2007-05-31 | 2008-12-11 | Teva Pharmaceutical Industries Ltd. | Process for the synthesis of ramelteon and its intermediates |
| US20090137842A1 (en) * | 2007-10-03 | 2009-05-28 | Vollerner Yuri | Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof |
| JP2010539156A (ja) * | 2007-10-23 | 2010-12-16 | テバ ファーマシューティカル インダストリーズ リミティド | ダサチニブ多形体およびその調製プロセス |
| US20090281176A1 (en) * | 2007-11-01 | 2009-11-12 | Vinod Kumar Kansal | Process for the synthesis of ramelteon and its intermediates |
| WO2009061513A1 (en) * | 2007-11-09 | 2009-05-14 | Thar Pharmaceuticals | Crystalline forms of lamotrigine |
| CA2717580A1 (en) * | 2008-03-06 | 2009-12-17 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities |
| US20100087525A1 (en) * | 2008-06-23 | 2010-04-08 | Lilach Hedvati | Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester |
| WO2010045565A1 (en) * | 2008-10-16 | 2010-04-22 | Teva Pharmaceutical Industries Ltd. | Process for the synthesis of ramelteon and its intermediates |
| CA2795023A1 (en) * | 2010-03-29 | 2011-10-06 | Pliva Hrvatska D.O.O. | Crystal forms of o-desmethylvenlafaxine fumarate |
| WO2012034065A1 (en) | 2010-09-09 | 2012-03-15 | Teva Pharmaceutical Industries Ltd. | Aliskiren intermediates and a process for analyzing the purity of aliskiren |
| CN102766104A (zh) * | 2012-08-20 | 2012-11-07 | 三金集团湖南三金制药有限责任公司 | 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法 |
| WO2015092819A2 (en) * | 2013-12-21 | 2015-06-25 | Nektar Therapeutics (India) Pvt. Ltd. | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine |
| CN110467560A (zh) | 2018-05-09 | 2019-11-19 | 深圳微芯生物科技股份有限公司 | 一种苯基氨基丙酸钠衍生物、其制备方法和应用 |
| KR102270026B1 (ko) * | 2020-01-31 | 2021-06-28 | 현대약품 주식회사 | (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법 |
| CN113156009B (zh) * | 2021-04-20 | 2023-12-22 | 三金集团湖南三金制药有限责任公司 | 高效液相色谱分析拉莫三嗪的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK153787C (da) | 1979-06-01 | 1989-01-16 | Wellcome Found | Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved |
| EP0021120B1 (en) | 1979-06-01 | 1983-04-06 | The Wellcome Foundation Limited | 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them |
| GB8613183D0 (en) | 1986-05-30 | 1986-07-02 | Wellcome Found | Triazine salt |
| GB9426448D0 (en) * | 1994-12-30 | 1995-03-01 | Wellcome Found | Process |
| WO1996020934A1 (en) * | 1994-12-30 | 1996-07-11 | The Wellcome Foundation Limited | Process for the preparation of lamotrigine |
| GB9512854D0 (en) * | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
-
1998
- 1998-06-10 GB GBGB9812413.4A patent/GB9812413D0/en not_active Ceased
-
1999
- 1999-02-24 EA EA199900159A patent/EA000666B1/ru not_active IP Right Cessation
- 1999-02-25 SG SG9901252A patent/SG85628A1/en unknown
- 1999-03-09 KR KR1019990007632A patent/KR100322354B1/ko active IP Right Review Request
- 1999-03-09 HR HR990074A patent/HRP990074A2/hr not_active Application Discontinuation
- 1999-03-10 DK DK99200695T patent/DK0963980T3/da active
- 1999-03-10 AT AT99200695T patent/ATE218552T1/de not_active IP Right Cessation
- 1999-03-10 CN CN99103445A patent/CN1238454A/zh active Pending
- 1999-03-10 ID IDP990201D patent/ID22957A/id unknown
- 1999-03-10 NO NO991151A patent/NO991151L/no unknown
- 1999-03-10 PL PL99331870A patent/PL331870A1/xx not_active Application Discontinuation
- 1999-03-10 AR ARP990101018A patent/AR014074A1/es not_active Application Discontinuation
- 1999-03-10 ZA ZA9901951A patent/ZA991951B/xx unknown
- 1999-03-10 EP EP99200695A patent/EP0963980B1/en not_active Expired - Lifetime
- 1999-03-10 EP EP01203376A patent/EP1170588A1/en not_active Withdrawn
- 1999-03-10 PE PE1999000190A patent/PE20000332A1/es not_active Application Discontinuation
- 1999-03-10 AU AU20319/99A patent/AU2031999A/en not_active Abandoned
- 1999-03-10 US US09/265,670 patent/US6333198B1/en not_active Expired - Fee Related
- 1999-03-10 CA CA002265194A patent/CA2265194C/en not_active Expired - Fee Related
- 1999-03-10 PT PT99200695T patent/PT963980E/pt unknown
- 1999-03-10 TR TR1999/00520A patent/TR199900520A2/xx unknown
- 1999-03-10 NZ NZ334590A patent/NZ334590A/xx unknown
- 1999-03-10 YU YU12399A patent/YU12399A/sh unknown
- 1999-03-10 BR BR9900984-6A patent/BR9900984A/pt not_active IP Right Cessation
- 1999-03-10 ES ES99200695T patent/ES2178342T3/es not_active Expired - Lifetime
- 1999-03-10 AP APAP/P/1999/001481A patent/AP9901481A0/en unknown
- 1999-03-10 DE DE69901656T patent/DE69901656T2/de not_active Expired - Fee Related
- 1999-03-10 HU HU9900592A patent/HUP9900592A3/hu unknown
- 1999-03-10 MA MA25489A patent/MA24777A1/fr unknown
- 1999-03-10 SI SI9930088T patent/SI0963980T1/xx unknown
- 1999-03-10 JP JP11063792A patent/JP2989189B1/ja not_active Expired - Fee Related
- 1999-03-10 AP APAP/P/2001/002286A patent/AP0102286A0/en unknown
-
2000
- 2000-01-17 UY UY25946A patent/UY25946A1/es unknown
- 2000-07-25 CN CN00122208A patent/CN1306210A/zh active Pending
-
2001
- 2001-09-06 AP AP2001002286A patent/AP2001002286A0/xx unknown
-
2003
- 2003-06-17 NO NO20032753A patent/NO20032753D0/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9900592A3 (en) | Process for testing the purity of pharmaceutical composition containing lamotrigine | |
| HUP0103511A3 (en) | Oxazole compounds and pharmaceutical compositions containing them and process for preparation the compounds | |
| HUP0201376A2 (en) | Thiazoloderivatives and pharmaceutical compositions containing them and process for preparation the compounds | |
| ZA9810490B (en) | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor | |
| IL133420A0 (en) | Pharmaceutical composition for combination of piperidinoalkanol-decongestant | |
| ZA962916B (en) | New arylglycineamide derivatives processes for the manufacture thereof and pharmaceutical compositions containing these compounds | |
| IL137494A0 (en) | Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same | |
| IL117620A0 (en) | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same | |
| IL137505A (en) | Pharmaceutical compositions containing tramadol | |
| EG22344A (en) | Process for preparing of novel pharmaceutical composition | |
| EP1106626A4 (en) | PREPARATION OF ORDINARY GLYCOPEPTIDES | |
| IL129906A0 (en) | Process for the preparation of beta-isophorone | |
| IL142534A0 (en) | Pharmaceutical compositions containing an antigen-adjuvent | |
| IL133140A0 (en) | Novel process for the preparation of 4-aryl-piperidines | |
| IL131392A (en) | Process for the preparation of substituted thiazolidinedione | |
| HUP0001308A3 (en) | (4-piperidinyl)-1h-2-benzopyran derivatives useful as antipsychotic agents, process for their preparation and pharmaceutical compositions containing the same | |
| IL131121A0 (en) | Process for the preparation of benzothiazolone compounds | |
| HUP0001441A3 (en) | Process for the preparation of pharmaceutical compositions containing 4-aza-androst-1-ene derivatives | |
| ZA987741B (en) | Process for the preparation of oxazaphosphorine-2-amines | |
| ZA200004376B (en) | Process for the preparation of tetrapeptide | |
| IL138843A0 (en) | Improved process for the manufacture of n- (1-cyanoalkyl) -2-phenoxypropionamide derivatives | |
| HUP9902745A3 (en) | Process for the preparation of benzylcarbazate | |
| HUP0103105A3 (en) | Process for the synthesis of exochelins | |
| GB9807032D0 (en) | Process for the preparation of (S)-3-carbethoxy-3-benzylpiperidine | |
| PL343270A1 (en) | Process for the preparation of nitroguanidine derivatives |